Fulcrum Therapeutics is a biopharmaceutical company that develops treatments for patients with genetically defined diseases. It has two product candidates: losmapimod for facioscapulohumeral muscular dystrophy and FTX-6058 for sickle cell disease and other hemoglobinopathies. In addition to its ongoing research for rare diseases, it has collaboration agreements with Acceleron Pharma and MyoKardia.